

April Program
MONDAY, APRIL 16, 2007

TOPIC: **Biogenerics' Effects on Product Development,
Commercialization and Licensing of Biologics**

SPEAKERS: **John M. Engel**
Managing Partner, Engel & Novitt, LLP

Robert Ward
Vice President, Commercial Development, NPS Pharmaceuticals Inc.

Michael J. Wise
Partner, Perkins Coie LLP

As the landscape for biogenerics (“follow-on proteins”) continues to evolve, innovators must re-evaluate their biologic development, commercialization, and licensing strategies. This session will offer an update on the latest U.S. legislative actions and important changes that are required for U.S. biologic development plans. Our three speakers will discuss how biosimilars will fragment the global biologic markets and mandate a change in commercial strategy in the U.S., EU, Japanese, and Emerging Markets. The session will also highlight key intellectual property/trade secrets that will be critical for remaining competitive in biotechnology.

Since our three speakers are experts in legal/regulatory, science policy, and legislative/political issues associated with follow-on biologics, this program provides an excellent chance to obtain important information that may be helpful in planning product development and life-cycle management.